Sajja Venkatesh on the Results of CREST-2 Trial
Sajja Venkatesh, Interventional Neurologist, FNB-NeuroVascular Intervention at Apollo Hospitals, shared on LinkedIn:
”CREST-2 Trial: Carotid artery stenting (CAS) vs Carotid Endarterectomy (CEA) for asymptomatic high-grade carotid stenosis (≥70%) who have not had recent stroke symptoms,
- Addition of CAS resulted in a reduced risk of a composite of perioperative stroke, death, or ipsilateral stroke within a 4 year timeframe, surpassing the outcomes achieved through intensive medical management alone.
- Conversely, CEA did not demonstrate a statistically significant advantage.
Primary Outcome:
– Stenting Trial: The 4-year incidence of stroke or death was significantly lower in the stenting group (2.8%) compared to the medical-therapy group (6.0%), with an absolute risk reduction of 3.2 percentage points (P=0.02).
– Endarterectomy Trial: No significant difference was observed between the endarterectomy group (3.7%) and the medical-therapy group (5.3%) (P=0.24).”
Read the full article here.
Article: Medical Management and Revascularization for Asymptomatic Carotid Stenosis
Authors: CREST-2 Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 26, 2026, 07:01Pedro Perez on Deep Vein Thrombosis in 2026: Getting the First Decisions Right
-
Jan 26, 2026, 05:40Vicki Kopplin Offers Immediate Funding for People With Bleeding Disorders
-
Jan 26, 2026, 05:27Jill Storry on Alloimmune Hemolytic Disease of the Fetus And Newborn
-
Jan 26, 2026, 05:09Wathsala Manindrani Gives a A Practical Perspective on Red Cell Exchange Transfusion
-
Jan 26, 2026, 04:59Abdul Mannan: BDUC – 4 Letters That Make Many Haematologists Uncomfortable
-
Jan 26, 2026, 04:51Manoj Kumar Singh: Power In Me Foundation Celebrates 2026 as Year Of Rare
-
Jan 26, 2026, 04:40Heghine Khachatryan: Did You Know VWD Comprises 3 Main Types?
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First